挪威奥斯陆大学医院肿瘤研究博士后职位

We seek 2 postdocs to work in the field of hematology/lymphoid malignancy/immunology and Cancer biology. These two postdocs will add to two very active research groups and participate in ongoing, well-funded projects at two internationally renowned research sites in Oslo, The Centre for Molecular Medicine Norway (NCMM) and The Centre for Immune Regulation (CIR).

Background:
The Centre for Molecular Medicine Norway (NCMM) was established in 2008 as a national partnership institution with the European Molecular Biology Laboratory together with similar centres in Sweden, Finland and Denmark under the Nordic EMBL Partnership with an overall objective of facilitating translation of discoveries in basic medical research into clinical practice. NCMM focuses particularly on disease mechanisms where Norway has clear strengths and investigates disease mechanisms in cancer, immune disorders and cardiovascular diseases.

The Taskén group in NCMM and Division of Medicine, OUS investigates signal networks and targeting strategies in immune cells and cancer cells. The group has established a Chemical Biology Screening Platform that serves the Oslo region and is now also starting projects developing Cancer Drug Sensitivity Screening (CDSS) pipelines for different cancers to support future individualized therapy programs.

Centre for Immune Regulation (CIR) is a research centre established as a Centre of Excellence by the Research Council of Norway at the University of Oslo and the Oslo University Hospital. CIR focuses on investigation of mechanisms of immune dysregulation in immune diseases and the development of therapeutics.

The Munthe group in CIR studies how dysregulated interactions between Th cells and B cells predispose for B cell cancer. They define how Th cells support and maintain B cell cancer in mice and humans and have focus on tumor microenviroment.

Together with the Department of Hematology the Tasken and Munthe groups have started a project (HSE-funded) entitled “Pipeline for individually tailoring new treatments for relapsed, intractable chronic lymphocytic leukemia and multiple myeloma.” The project will establish a pipeline to identify drugs and drug combinations effective in personalized therapy of individual patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), in whom other treatment options are exhausted or ineffective. The research focuses on the pathogenesis of chronic lymphocytic leukemia (CLL) and myeloma in patients and will identify pathway aberrations amenable for drug targeting in a personalized medicine context. Lab work will involve phosphoflow cytometry pathway analysis, CDSS using flow cytometry, viability and growth inhibition assays, novel in vitro culture assays of primary cancer cells being developed, and patient-derived xenografting (PDX) into NSG mice and other models.

At the moment we are jointly searching for two postdoctoral researchers for the above project

Post-doctoral research fellow 1 – Cancer Drug Sensitivity Screening (Taskén group): The successful candidate will work with establishing screening assays and the pipeline for CDSS, library optimization, patient sample analysis and data interpretation.

Post-doctoral research fellow 2 – Tumor microenvironment and (Munthe group): The successful candidate will work with CLL and MM tumor microenviroment leading to understanding of in vitro culture condition necessary to support CDSS and PDX and test drug combinations in PDX.

Post-doctoral candidates:

We seek highly motivated individuals holding a PhD or M.D.-PhD degree that appreciates working in an international and interactive environment. Qualification requirements include a completed PhD and experience within the field of chemical biology, cancer biology, hematology, tumor immunology, translational medicine or related fields. Both applicants must be proficient in flow cytometry. For position 1 experience in chemical biology and/or CDSS is necessary. For position 2, Felasa-C licence and documented experience from working with mice is a requirement and experience with PDX a benefit. The ideal candidates should have a strong background in a relevant field as indicated above with a specific interest in working on a collaborative translational research project. Furthermore a strong background in lab-automation and/or high-throughput flow cytometry for studying cancer cell signaling and a specific interest in chemical biology and CDSS or vice versa would be a benefit (position 1) Similarly, a strong background in B cell malignancies and tumor microenvironment and an specific interest in primary cell culture and PDX or vice versa would be a benefit (position 2). Experience with working with clinical samples would also be a benefit (both positions).

Applications should include a covering letter summarizing the applicant’s career, past research accomplishments and showing how the applicant would fit the call (1-2 pages), include a CV and a list of publications, copies of certificates and grades, and names of three references. Please indicate whether the application is for position 1 or 2.

Postdoctoral-positions will be placed with a starting salary of NOK 491.000 (52 000 Euros). The positions are for three years with preferred start as soon as possible and within the second quarter of 2015.